Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-04-04
2010-10-05
Chung, Susannah (Department: 1626)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S063000, C548S255000, C548S300100
Reexamination Certificate
active
07807394
ABSTRACT:
The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.
REFERENCES:
patent: 5674693 (1997-10-01), Raleigh et al.
patent: WO 9604249 (1996-02-01), None
patent: WO 0112575 (2001-02-01), None
Adams, G. “Hypoxia-mediated drugs for radiation and chemotherapy.” Cancer (1981), 48:696-707.
Bentzen, et al. “Feasibility of detecting hypoxia in experimental mouse tumours with18F-fluorinated tracers and positron emission tomography: a study evaluating [18F]-Fluoromisonidazole and [18F]Fluoro-2-deoxy-D-glucose.” Acta. Oncol. (2000), 39:629-637.
Brizel, et al. “Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.” Cancer Res. (1996), 56:941-943.
Clifford Chao, et al. “A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.” Int. J. Radiat. Oncol. Biol. Phys. (2001), 49:1171-1182.
Fujibayashi, et al. “Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.” J. Nucl. Med. (1997), 38:1155-1160.
Gronroos, et al. “Pharmacokinetics of [18F]-FETNIM. A potential hypoxia marker for PET.” J. Nucl. Med. (2001), 42:1397-1404.
Hockel, et al. “Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix.” Cancer Res. (1996), 56:4509-4515.
Huisgen. 1,3-Dipolar Cycloaddition Chemistry (vol. 1) (Padwa, A., ed.), pp. 1-176, Wiley, 1984.
Hustinx, et al. “Non-invasive detection of tumor hypoxia using the 2-nitroimidazole18F-EF1.” J. Nucl. Med. (1999), 4:99P (abstract 401). See J. Nucl. Med. (1999), 41(2):327-336.
Ishikawa, et al. “Development of [18F]FRP-170 injection for imaging hypoxia by PET.” Kaku Igaku. (2005), 42:1-10. [Article in Japanese. English Abstract obtained].
Jorgensen, K. “Catalytic Asymmetric Hetero-Diels-Alder Reactions of Carbonyl Compounds and Imines.” Angew. Chem. Int. Ed. Engl. 2000, 39, 3558-3588.
Kolb, et al. “Click Chemistry: Diverse Chemical Function from a Few Good Reactions.” Angewandte Chemie, International Edition (2001), 40:2004-2021.
Kolb, et al. “The Growing impact of click chemistry on drug discovery.” Drug Discovery Today (2003), 8:1128-1137.
Krasinski, et al. “Direct Synthesis of 1,5-Disubstituted-4-magnesio-1,2,3-triazoles, Revisited.” Organic Letters (2004), 6:1237-1240.
Lee, et al. “A Potent and Highly Selective Inhibitor of Human alpha-1,3-Fucosyltransferase via Click Chemistry.” Journal of the American Chemical Society (2003), 125:9588-9589.
Lewis, et al. “Click Chemistry In Situ: Acetylcholinesterase as a Reaction Vessel for the Selective Assembly of a Femtomolar Inhibitor from an Array of Building Blocks.” Angew. Chem., Int. Ed. (2002), 41:1053-1057.
Manetsch, et al. “In-situ Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications.” Journal of the American Chemical Society (2004), 126:12809-12818.
Mocharla, et al. “In-situ Click Chemistry: Enzyme-Generated Inhibitors of Carbonic Anhydrase II.” Angew. Chem. Int. Ed. (2005), 44:116-120.
Moulder, et al. “Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data.” Int. J. Radiat. Oncol. Biol. Phys. (1984), 10:695-712.
Nordsmark, et al. “Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck.” Radiother. Oncol. (1996), 41:31-39.
Rasey, et al. “Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole.” Radiat. Res. (2000), 153:84-92.
Rostovtsev, et al. “A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes.” Angewandte Chemie, International Edition (2002), 41:2596-2599.
Seddon, et al. “The role of functional and molecular imaging in cancer drug discovery and development.” Brit. J. Radiol. (2003), 76:S128-S138.
Tietze, et al. “Hetero Diels-Alder Reactions in Organic Chemistry.” Top. Curr. Chem. 1997, 189, 1-120.
Tornoe, et al. “Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides.” Journal of Organic Chemistry (2002), 67:3057-3064.
Vaupel, et al. “Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2tension measurements.” Cancer Res. (1991), 51:3316-3322.
Wang, et al. “Bioconjugation by Copper(I)-Catalyzed Azide-Alkyne [3+2] Cycloaddition.” Journal of the American Chemical Society (2003), 125:3192-3193.
Wang, et al. “Positron Emission Tomography: Applications in Drug Discovery and Drug Development.” Curr. Top. Med. Chem. (2005), 5:1053-1075.
Whiting, et al. “Inhibitors of HIV-1 Protease by using In-Situ Click Chemistry.” Angew. Chem. (2006), 118:1463-1467. (Same as Angew. Chem. Int. Ed. Engl. (2006), 45:1435-1439.).
Yang, et al. “Development of18F-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.” Radiology (1995), 194:795-800.
Dr. Richard A. Houghten and Michael Lebl, “Peptides: The Wave of the Future”, 2nd International Peptide Symposium in conjunction with the 17th American Peptide Symposium, Jun. 9-14, 2001, San Diego, California.
Collier Thomas Lee
Duclos Brian A.
Gangadharmath Umesh B.
Gao Zhiyong
Karimi Farhad
Chung Susannah
Ryan Joshua B.
Siemens Medical Solutions USA , Inc.
LandOfFree
Nitro-imidazole hypoxia imaging agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitro-imidazole hypoxia imaging agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitro-imidazole hypoxia imaging agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4206148